Savara Inc Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Savara Inc (SVRA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $1.92 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-13
- Savara Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2017-03-31 was $50.21, a 4155.08% increase year-over-year.
- Savara Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2016-03-31 was $1.18, a 103.45% increase year-over-year.
- Savara Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.58.
- Savara Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $1.92, a 7.87% increase from fiscal 2024.
- Savara Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $1.78, a 37.98% increase from fiscal 2023.
- Savara Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $1.29, a 14.57% decline from fiscal 2022.
- Savara Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $1.51, a 53.54% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.92 10-K · filed 2026-03-13 | |||
| 2024-12-31 | $1.78 10-K · filed 2025-03-27 | |||
| 2023-12-31 | $1.29 10-K · filed 2024-03-07 | |||
| 2022-12-31 | $1.51 10-K · filed 2023-03-30 | |||
| 2021-12-31 | $3.25 10-K · filed 2022-03-30 | |||
| 2017-03-31 | $50.21 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $0.79 10-K · filed 2017-03-06 | |||
| 2016-09-30 | $0.98 10-Q · filed 2016-11-08 | |||
| 2016-06-30 | $0.90 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $1.18 10-Q · filed 2016-05-06 | |||
| 2015-12-31 | $0.65 10-K · filed 2016-03-14 | |||
| 2015-09-30 | $0.66 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $0.59 10-Q · filed 2015-08-12 | |||
| 2015-03-31 | $0.58 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $0.78 10-K · filed 2015-03-24 | |||
| 2014-09-30 | $0.78 10-Q · filed 2014-10-31 | |||
| 2014-06-30 | $6.18 10-Q · filed 2014-08-11 | |||
| 2013-12-31 | $0.88 10-K · filed 2014-03-26 | |||
| 2013-09-30 | $0.74 10-Q · filed 2013-11-04 | |||
| 2012-12-31 | $2.25 10-K · filed 2013-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |